Find information on thousands of medical conditions and prescription drugs.

Behcet syndrome

Behçet’s disease, (formerly known as Behçet’s syndrome), is a chronic condition due to disturbances in the body’s immune system. This system, which normally protects the body against infections by producing controlled inflammation, becomes overactive and produces unpredictable outbreaks of exaggerated inflammation. This extra inflammation affects blood vessels, usually the small ones. As a result, symptoms occur wherever there is a patch of inflammation, and can be anywhere where there is a blood supply. (Taken from


Bacterial endocarditis
Bacterial food poisoning
Bacterial meningitis
Bacterial pneumonia
Bangstad syndrome
Bardet-Biedl syndrome
Bardet-Biedl syndrome
Bardet-Biedl syndrome
Bardet-Biedl syndrome
Barrett syndrome
Barth syndrome
Basal cell carcinoma
Batten disease
Becker's muscular dystrophy
Becker's nevus
Behcet syndrome
Behr syndrome
Bell's palsy
Benign congenital hypotonia
Benign essential tremor...
Benign fasciculation...
Benign paroxysmal...
Berdon syndrome
Berger disease
Bicuspid aortic valve
Biliary atresia
Binswanger's disease
Biotinidase deficiency
Bipolar disorder
Birt-Hogg-Dube syndrome
Bloom syndrome
Blue diaper syndrome
Blue rubber bleb nevus
Body dysmorphic disorder
Bourneville's disease
Bowen's disease
Brachydactyly type a1
Bright's disease
Brittle bone disease
Bronchiolotis obliterans...
Bronchopulmonary dysplasia
Brown-Sequard syndrome
Brugada syndrome
Bubonic plague
Budd-Chiari syndrome
Buerger's disease
Bulimia nervosa
Bullous pemphigoid
Burkitt's lymphoma
Cavernous angioma


Behçet's disease is named after Hulusi Behçet (1889-1948), the Turkish dermatologist and scientist who first recognized the syndrome in one of his patients in 1924 and reported his research on the disease in Journal of Skin and Veneral Diseases in 1936. The name (Morbus Behçet) was formally adopted at the International Congress of Dermatology in Geneva in September 1947.

Benedikt Adamandiades, a Greek ophthalmologist, reportedly described the disease six years before Behçet did. Nevertheless, only Greek scientists refer to the disease Adamantiades-Behçet's or even Adamantiades' disease.

Behçet's disease was probably first described by Hippocrates in the 5th century.

Pronunciation note

Because it contains a cedilla, "Behçet" is frequently wrongly assumed to be French in origin and pronounced with a sibilant "s" sound (as in "satsuma") or soft "ch" (as in "shoe"), with and the "t" incorrectly silenced: "Beshay". Because Hulusi Behçet was Turkish, the correct pronounciation is with a hard "ch", as in "church", and with the terminal "t" sounded: "Bet-chet".


The symptoms of Behçet's disease are believed to be caused by an over-active immune system which, without any apparent infections, produces recurrent outbreaks of inflammation in small blood vessels. Common symptoms include mouth ulcers, sore genitals and eye inflammation, and arthritis in older patients, mostly painful but not life-threatening conditions. However, some patients may be unable to work because of the pain and the impaired vision and mobility. In some severe cases, uncontrolled inflammation may lead to blindness, intestinal complications, stroke, and even meningitis, which can be fatal.

This disease usually first strikes patients in their 20s and 30s. It then becomes a fluctuating lifelong disorder with a series of remissions and exacerbations which can be from days to months. Complete remission is rare.


There is no specific pathological test for Behçet’s disease at present. It is diagnosed clinically by specific patterns of symptoms and repeated outbreaks. Other causes for these symptoms have to be ruled out before making the diagnosis. The symptoms do not have to occur together, but can have happened at any time.

There are three levels of certainty for diagnosis:

  1. International Study Group diagnostic guidelines (very strict for research purposes)
  2. Practical clinical diagnosis (generally agreed pattern but not so strict)
  3. 'Suspected' or 'Possible' diagnosis (incomplete pattern of symptoms)


[List your site here Free!]

Intracardiac Thrombus in Behcet's Disease - )
From CHEST, 8/1/00 by Nesrin Mogulkoc

A Systematic Review

Background: Intracardiac thrombus formation is a rare but serious complication of Behcet's disease. We aimed to review the clinical and pathologic correlates of cardiac thrombus formation in the context of Behcet's disease.

Methods and results: A comprehensive search of the medical literature was conducted using MEDLINE including bibliographies of all selected articles. Although the disease has a unique geographic distribution, being most common in the population of the ancient Silk Route, cases complicated by intracardiac thrombus have mostly originated from the Mediterranean basin and the Middle East. Young men appear to be most at risk, with the right heart the most frequent site of involvement. The first symptoms and signs of the disease frequently precede systemic organ manifestations. In those cases in which intracardiac thrombus occurs, it is apparent in more than half of cases on first recognition of the disease.

Conclusion: A diagnosis of Behcet's disease should be considered if a patient presents with a mass in the right-sided cardiac chambers, even in the absence of the characteristic clinical features of the condition. This is particularly applicable if the patient is a young man from the Mediterranean basin or the Middle East.

(CHEST 2000; 118:479-487)

Key words: Behcet's disease; Behcet's syndrome; cardiac involvement; cardiac thrombus

Abbreviations: ESR = erythrocyte sedimentation rate; HLA = human leukocyte antigen

Behcet's disease is a multisystemic inflammatory disease especially frequent among the Japanese and Mediterranean basin population. Its unique geographic distribution is associated with the prevalence of certain human leukocyte antigen (HLA)-B antigens, especially HLA-B5 and HLA-B51.[1] The disease is difficult to diagnose, and in the absence of a definitive diagnostic laboratory test, reliance is on characteristic clinical features. Orogenital ulceration is so constant that it is a cornerstone of the diagnosis, which can be made with increased confidence in the presence of concomitant ocular involvement, arthritis, skin lesions, CNS, or cardiac disease. The first manifestations of the disease may precede the appearance of other symptoms and signs essential for the diagnosis by many years.[2] Venous and arterial vasculitis can be demonstrated in up to one third of patients,[3] but despite the multisystem involvement, cardiac pathology has been reported relatively infrequently. Pancarditis, acute myocardial infarction, conduction system disturbances, and valvular disease have all been described.[4] Intracardiac thrombus formation is very uncommon. We conducted a cumulative literature search in which we were able to find only 24 cases previously published in 21 reports[3,5-24] in which Behcet's disease was associated with intracardiac thrombus. We reviewed the clinical and pathologic correlates of cardiac thrombus formation in the context of Behcet's disease.


Search Strategy

To identify the relevant literature we used computerized literature searches of the National Library of Medicine's MEDLINE from 1966 to April 1999 using the key words Behcet's disease or Behcet's syndrome, each together with cardiac thrombus, cardiac thrombi, cardiac involvement, or cardiac lesion. The searches were inclusive of al languages. Bibliographies of all articles were reviewed for other relevant articles.

Diagnostic Criteria

Diagnosis requires the presence of oral ulceration in addition to any two of four additional features[25]: genital ulceration, ocular involvement, positive pathergy test, or skin manifestations (erythema nodosum, papulopustular lesions, acneiform nodules, pseudofolliculitis). Other features not considered essential for the diagnosis, but potentially useful in an individual ease, include subcutaneous thrombophlebitis, deep vein thrombosis, arterial occlusion or aneurysm, GI ulceration, epididymitis, CNS involvement, arthritis, and a family history of the condition. All included patients fulfilled the diagnostic criteria.


A total of 21 relevant articles including 24 cases were identified, of which four were written in French. We also included a 19-year-old Turkish patient as a 25th case, observed for 3 years (N.M.).



Of the 25 Behcet's patients with intracardiac thrombus, 21 (84%) originally came from the ancient Silk Route areas. Nineteen of these 21 patients (90%) were confined to Mediterranean basin regions or the Middle East (Turkish, 5; Arabian, 5; North African, 5; French, 2; Israeli, 1; and Sicilian, 1). The male to female ratio was 23:2, and the mean age was 28 years (range, 12 to 51 years; Table 1). Five patients with an established diagnosis of Behcet's disease were receiving specific drug therapy (prednisone, colchicine, cyclophosphamide, and indomethacin).

Table 1--Summary of Published Behcet's Cases Complicated by Intracardiac Thrombus: Principal Clinical Features(*)

(*) Aza = azathioprine; Colc = colchicine; CyA = cyclosporin; CycloP = cyclophosphamide; Indo = indomethacin; Nil = no treatment; NS = not stated; Pred = prednisone; Neg = negative.

([dagger]) Patients diagnosed as having incomplete Behcet's disease in the original article.

([double dagger]) Patients with a diagnosis of Behcet's disease before intracardiac thrombus.

Presenting Clinical Features of Intracardiac Thrombus

Relationship Between Concurrent Clinical Features, Activity, and Course of Disease: Intracardiac thrombus was clearly stated to be a presenting feature in more than half (13 of 23) of the patients. However, for other patients, its detection was up to 25 years after the onset of the disease (2 months to 25 years). At the time of detection of intracardiac thrombus, fever, hemoptysis, dyspnea, and cough were the predominant symptoms (seen in 52%, 48%, 44%, and 20% of patients, respectively; Table 2). Organomegaly was present in 28% of patients. A pathergy test was stated to be positive in 11 patients and negative in 2. HLA B5/B51 positivity was noted in six of the eight patients tested. The erythrocyte sedimentation rate (ESR) had been recorded in 14 patients (Table 3): values were significantly elevated in all but one (patient 13), with an average maximum recorded ESR of 76 mm/h.

(*) BD = Behcet's disease; B = biopsy; C = cardiomegaly; Dyspnea; H = hepatomegaly; Hemop = hemotysis; LPD = lymphoproliferative disease; N = necropsy; Org = organomegaly; PTE = pulmonary thromboembolism; RHAC = right heart angiocardiogram; Spl = splenomegaly; S = surgery; SVCS = superior vena cava syndrome; TEE = transesophageal echocardiography; TTE = transthoracic echocardiography; TB = tuberculosis; VT = venous thrombosis. See Table 1 for other abbreviations.

([dagger]) Disease duration denotes interval between recognition of Behcet's disease and presentation with intracardiac thrombus.

Vascular and Pulmonary Involvement: Involvement of large arteries occurred in 12 patients. In 10, this took the form of pulmonary artery aneurysm formation, either alone or in association with renal artery or aortic involvement (Table 3). Fourteen (56%) patients had venous thrombosis (Table 3). Vena cava thrombosis was observed in seven (28%). In five patients, this was located in the superior vena cava, and in two, the inferior vena cava. Two patients had superior sagittal sinus and right transverse sinus thrombosis. In two patients, thrombosis of the hepatic veins or inferior vena cava caused the Budd-Chiari syndrome (patients 15 and 25). Pulmonary thromboembolism was seen in 13 patients (52%; Table 3). In seven of these 13 (54%), thrombophlebitis was observed in the major vessels and may have been the source of the embolus. Four patients were said to have pulmonary vasculitis.

Table 3--Associated Clinical Features at Time of Intracardiac Thrombus or During Follow-up(*)

(*) APA = aortic pseudoaneurysm;

IVC = inferior vena cava;

PAA(s) = pulmonary artery aneurysm(s);

SVC = superior vena cava. See Tables 1 and 2 for other abbreviations.

Incidence of Valvular Heart Disease and Cardiac Failure: The presence of thrombus within the right heart was associated with tricuspid valve involvement in five patients. This was the most commonly involved valve. In three patients, thrombus interfered with the functional integrity of the valve (patients 17, 22, and 25). In the other two patients, the valve leaflets were either thickened or replaced by fibrous tissue (patients 2 and 14). Five patients experienced right heart failure at some point in the clinical course: cardiac failure was unaccompanied by valvular pathology in two (patients 1 and 9).

Differential Diagnosis

The clinical presentation of intracardiac thrombus was nonspecific in the majority of patients. The most common misdiagnosis on the basis of the echocardiographic appearances was a primary cardiac tumor, this diagnosis being made initially in seven patients (Table 2). In four of these, histopathologic examination was required for the diagnosis of intracardiac thrombus, and in one (patient 7), it was inferred after resolution of a right ventricular apical mass occurred with a prolonged infusion of streptokinase (Table 4). One patient had diagnosis at necropsy (patient 17).

(*) LV = left ventricle;

PA = pulmonary artery;

RV = right ventricle.

See Tables 1, 2, and 3 for other abbreviations.


The exact sites of the lesions were variable. Most were in the right side of the heart. Those in the right atrium were variably attached to the free wall (patients 6, 12, and 22) or the septum (patient 12), extended into the superior (patient 12) or inferior (patient 15) venae cavae or protruded through the tricuspid valve (patient 21), and varied from small (patients 6 and 15) to massive (patient 12). Those in the right ventricle were attached to the free wall (patient 6) or the annulus of the tricuspid valve (patient 14) and again varied from small (patient 5) to massive (patient 6). There were only three reports of involvement of the left ventricle (patients 6, 8, and 18) and one of the left atrium (patient 13). Lesions were sometimes multiple in one (patient 5) or multiple chambers (patients 6 and 23).

The histologic appearances of the lesions within the chambers were usually those of an organizing thrombus (patients 11 through 14, 16, 21, 22, and 25), although sometimes there were foci of new thrombus formation (patients 12 and 22). The organizing thrombus usually contained an inflammatory cell infiltrate composed of a mixture of granulocytes and mononuclear inflammatory cells (patients 1 and 22) or predominantly lymphocytes (patient 16). The myocardium underlying the site of attachment of the thrombus was either normal (patients 6 and 21) or deeply infiltrated by inflammatory cells extending from the overlying thrombus (patient 1). Again, the inflammatory infiltrate within the myocardium varies from mixed neutrophil granulocytes and mononuclear cells (patient 1) to one consisting of lymphocytes and plasma cells admixed with histiocytes and a small number of eosinophils (patient 5). There was sometimes marked myocardial fibrosis (patient 19), which in some cases incorporated the valve leaflets (patients 2 and 19), and calcification occurred within the fibrous tissue in one case (patient 18).

Diagnostic Modality

Intracardiac thrombus was detected in three patients at necropsy and in one additional patient intraoperatively (Table 2). In all remaining patients, two-dimensional echocardiography was used at some point during investigation. This technique accurately determined the involved cavity and often it was possible to ascertain the site of attachment of the thrombus and nature of any associated disease. A transesophageal study was used in five cases (patients 10, 11, 23, 24, and 25). Other imaging modalities including CT scan and MRI were used less frequently. Cineangiography of the right heart was used in three cases (patients 5, 7, and 23).

Treatment, Clinical Course, and Outcome

Surgery, performed in nine patients for exploratory reasons, was the first attempted treatment modality in 12 patients (Table 5). Surgery was unsuccessful in four patients. In one, the mass was found to be infiltrating extensively and was not completely resectable (patient 12). Subsequent treatment with prednisone and cyclophosphamide was unsuccessful, and the patient died after a massive hemoptysis from a ruptured pulmonary artery aneurysm. Three other patients died postoperatively. The cause in two was uncontrollable bleeding from the pulmonary vasculature. One died of unknown reasons (patient 9). Five of the six survivors remained well at follow-up, and one (patient 16) had two recurrences of intracardiac thrombus after initial surgery and remained stable on warfarin after the second surgical procedure. Two of the 11 patients treated surgically were lost to follow-up.

(*) ICT = intracardiac thrombus;

IST = immunosuppressive therapy;

LMWH = low molecular weight heparin.

See Tables 1, 2, and 3 for other abbreviations.

Anticoagulant or thrombolytic therapy was the first-line treatment in eight patients. In seven, this was associated with complete resolution of intracardiac thrombus, with recurrence in one patient at 2 years (patient 22; initial treatment had included immunosuppressive therapy). Two patients were treated with prednisone alone, with resolution of symptoms, but the outcomes were not recorded (patients 4 and 23). Three patients received no specific therapy for intracardiac thrombus because it was recognized only at autopsy. The reasons for death in this group were infection, massive hemoptysis, and pulmonary thromboembolism.


Although Behcet's disease is found in a broad geographic band stretching from the Mediterranean basin to the Far East, Behcet's disease complicated by intracardiac thrombus seems to be confined predominantly to patients from the Mediterranean basin and the Middle East. This mostly includes inhabitants of the old greater Ottoman Empire that extended well into the Balkans and across the Mediterranean littoral areas, where the incidence and prevalence still far exceed those elsewhere. It is well recognized that GI involvement in Behcet's disease is common in Japan but rare in Turkey[26]; conversely we have found only one case complicated by intracardiac thrombus among Far Eastern patients. This is consistent with the geographic variability in mode of clinical presentation and systemic organ involvement, suggesting that genetic predisposition may be highly relevant in determining systemic organ involvement in the disease.[27,28] There is evidence from heat shock protein studies for the implication of infective agents in Behcet's disease.[29] That the susceptibility of a certain population to this rare complication could be attributable to the variation in the presence of environmental factors, such as bacterial or viral agents (possibly mediated by meteorologic factors), is an attractive hypothesis.

In considering the full clinical spectrum of the disease, we found that women are far outnumbered by men. In severe disease, such as ocular, pulmonary arterial, and CNS involvement, this is particularly noticeable.[30] We have found a similar pattern in cases complicated by intracardiac thrombus, with a very marked predominance of men (only two cases occurring in women). Notably, even conditions exhibiting estrogen dependence, such as thrombophlebitis, are predominantly encountered in men with BehCet's disease rather than women.[30] The severe systemic manifestations also affect a younger age group,al We have found intracardiac thrombus to be more common in young patients with the condition. The classic features of Behcet's disease usually emerge in the third decade,[31] but 29% of patients with intracardiac thrombus presented in the second decade.

There is a considerable body of knowledge about the presence of autoreactive antibodies against oral mucosa in Behcet's patients.[32,33] Antiphospholipid antibodies have been identified in one patient with Behcet's disease and intracardiac thrombi: a causative role has been suggested (patient 23). Antiendothelial cell antibodies have been associated with vascular involvement.[34] However, there is no published evidence specific to intracardiac thrombosis. It is not known whether the anti-endothelial cell antibodies are also directed against antigens presented by endocardial cells.

Some of the manifestations of Behcet's disease have been considered to result from neutrophil hyperactivity.[35] Increased chemotaxis, active oxygen overproduction, and increased endothelial cytotoxicity have been implicated. Although the histologic descriptions of both the thrombi and the myocardium show some variation, mononuclear inflammatory cells, rather than neutrophils, predominate. The exact composition of the inflammatory infiltrate may be dependent on the timing of the biopsy.

Intracardiac thrombus is uniformly associated with an elevated ESR but it is recognized that this is a poor indicator of disease activity. Plasma endothelin-1 levels appear to correlate better.[36]

The reason for the propensity to right-sided intracardiac thrombus in Behcet's disease is still unclear. On the basis of autopsy findings, it could be postulated that endomyocardial fibrosis has a role in the development of intracardiac thrombus in some patients. However, it is difficult to know whether the thrombi are secondary to underlying endocarditis or endomyocardial fibrosis, since some case reports describe normal underlying myocardium. Comparison with the endomyocardial fibrosis seen in both hypereosinophilic syndrome and carcinoid syndrome has been made,[18] but in these conditions, the valves are rarely involved. The right-sided predominance of cardiac disease in carcinoid syndrome is explained by the presence of metastatic carcinoid in the liver and the greater exposure of the right heart to serotonin, which is cleared in the pulmonary circulation. Hypereosinophilic syndrome affects both ventricles equally.

It is well established that Behcet's disease predisposes strongly to venous and arterial thrombosis (present in up to one third of cases), and elevated von Willebrand factor antigen levels have recently been demonstrated.[37] Recurrent superficial and deep thrombophlebitis of the lower extremities are the most common abnormalities, followed by vena cava thrombosis, which was observed in six patients in this series. However, 6 of the 12 patients who had pulmonary arterial thrombosis were free of peripheral thrombus. In those patients with intracardiac thrombus, there is tight attachment of the thrombus to the endocardium or myocardium. For this reason, thromboembolism from a cardiac cavity has previously been deemed to be relatively uncommon.[3] Moreover, in some patients, the pulmonary abnormalities were seen to resolve after administration of immunosuppressive treatment rather than anticoagulation.[7,10,11] It is, therefore, possible that the pulmonary involvement is a result of in situ pulmonary pathology rather than embolization from a systemic vein. The lack of a clear understanding into the pathophysiology of pulmonary involvement has frequently hindered the interpretation of pulmonary perfusion defects in this condition.

The diagnosis of intracardiac thrombus is difficult in the context of the nonspecific clinical features of pyrexia and malaise, these symptoms commonly being attributed to endocarditis. The echocardiographic appearances are easily confused with those of large vegetation or more frequently with an intracardiac tumor. The differentiation from atrial myxoma is made more difficult by the fact that the appearances of a right atrial myxoma may be atypical and the surface may be covered by thrombus. In the absence of Behcet's disease, intracardiac thrombus is often found to overlie an akinetic myocardial segment.[38] However, right ventricular dysfunction was not always present in our series, and in patients with a right atrial thrombus, it was often seen to prolapse through the tricuspid valve into the right ventricle. Usually, the mass is relatively immobile, with a broad-based attachment. Transthoracic imaging may fail to determine the site of endocardial attachment, and a transesophageal study is more likely to accurately demonstrate anatomic relationships. Both intracardiac thrombus and cardiac tumors can give rise to pulmonary embolic phenomena, the latter causing right heart failure.[39]


Behcet's disease complicated by intracardiac thrombus most commonly occurs in the Mediterranean basin and Middle East, in young men. It usually involves the right side of the heart and often precedes other manifestations of Behcet's disease. There is frequently coexistence of cardiac and pulmonary complications, the latter commonly being responsible for death. The management of intracardiac thrombus has varied, the aim being to eradicate the thrombus and prevent recurrence. Surgical removal has the advantage of providing material for histologic examination and verification of the diagnosis. However, in the small number of cases in the published literature, medical management has been associated with a better outcome. Irrespective of the mode of management, the presence of intracardiac thrombus confers a poor prognosis, with many fatalities in these young patients.


[1] Mizuki N, Inoko H, Ohno S. Pathogenic gene responsible for the predisposition to Behcet's disease. Int Rev Immunol 1997; 14:33-48

[2] Augarten A, Yahav Y, Szeinberg A, et al. HLA-B5 in the diagnosis of Behcet's disease. J Med 1995; 26:133-138

[3] Koc Y, Gullu I, Akpek G, et al. Vascular involvement in Behcet's disease. J Rheumatol 1992; 19:402-410

[4] Ozkan M, Emel O, Ozdemir M, et al. M-mode, 2-D and Doppler echocardiographic study in 65 patients with Behcet's syndrome. Eur Heart J 1992; 13:638-641

[5] Davies JD. Behcet's syndrome with haemoptysis and pulmonary lesions. J Pathol 1973; 109:351-356

[6] Buge A, Escourolle R, Chomette G, et al. Maladie de Behcet avec manifestations neurologiques et fibrose endocardique du coeur droit: etude anatomoclinique d'une observation. Ann Med Interne (Paris) 1977; 128:411-419

[7] Candan I, Erol C, Sonel A, et al. Behcet's disease: cardiac and pulmonary involvement. Eur Heart J 1986; 7:999-1002

[8] Augarten A, Apter S, Theodor R. Right ventricular thrombus and pulmonary arteritis in Behcet's disease. Isr J Med Sci 1987; 23:900-901

[9] Lie JT. Cardiac and pulmonary manifestations of Behcet syndrome. Pathol Res Pract 1988; 183:347-352

[10] Vanhaleweyk G, El-Ramahi KM, Hazmi M, et al. Right atrial, right ventricular and left ventricular thrombi in (incomplete) Behcet's disease. Eur Heart J 1990; 11:957-959

[11] El-Ramahi KM, Fawzy ME, Sieck JO, et al. Cardiac and pulmonary involvement in Behcet's disease. Scand J Rheumatol 1991; 20:373-376

[12] Pottiez Y, Francois D. Thrombus intraventriculaire (iatrogene?) et maladie de Behcet. Rev Rhum 1991; 58:543-544

[13] Sayin AG, Vural FS, Bozkurt AK, et al. Right atrial thrombus mimicking myxoma and bilateral pulmonary artery aneurysms in a patient with Behcet's disease: a case report. Angiology 1993; 44:915-918

[14] Madanat WY, Prokaeva TB, Kotel'nikova GP, et al. Endocarditis with left atrial thrombus formation in Behcet's disease mimicking myxoma. J Rheumatol 1993; 20:1982-1984

[15] Mendes LA, Magraw LL, Aldea GS, et al. Right ventricular thrombus: an unusual manifestation of Behcet's disease. J Am Soc Echocardiogr 1994; 7:438-440

[16] Islim IF, Gill MD, Situnayake D, et al. Successful treatment of right atrial thrombus in a patient with Behcet's disease. Ann Rheum Dis 1994; 53:550-551

[17] Nakata Y, Awazu M, Kojima Y, et al. Behcet's disease presenting with a right atrial vegetation. Pediatr Cardiol 1995; 16:150-152

[18] Soulami S, Nour-Eddine M, Azzouzi L, et al. Fibrose endomyocardique du coeur droit au cours de la maladie de Behcet. Arch Mal Coeur Vaiss 1996; 89:917-921

[19] Huong DL, Wechsler B, Papo T, et al. Endomyocardial fibrosis in Behcet's disease. Ann Rheum Dis 1997; 56:205-208

[20] Huong DL, Dolmazon C, De Zuttere D, et al. Complete recovery of right intraventricular thrombus and pulmonary arteritis in Behcet's disease. Br J Rheumatol 1997; 36:130-132

[21] Roguin A, Edoute Y, Milo S, et al. A fatal case of Behcet's disease associated with multiple cardiovascular lesions. Int J Cardiol 1997; 59:267-273

[22] Kirali K, Civelek A, Daglar B, et al. An uncommon complication of Behcet's disease: intracardiac thrombosis needing surgical treatment. Thorac Cardiovasc Surg 1998; 46:102-105

[23] Harmouche H, Tazi Mezalek Z, Adnaoui M, et al. Association aneurysme de l'artere pulmonaire, thromboses intracardiaques et anticorps antiphospholipides au cours de la maladie de Behcet: a propo d'un cas. Rev Med Interne 1998; 19:512-515

[24] Duchene F, Berthier S, de Wazieres B, et al. Behcet's disease with cardiac and pulmonary manifestations. Presse Med 1998; 27:1674-1676

[25] International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990; 335:1078-1080

[[26] Yurdakul S, Tuzuner N, Yurdakul I, et al. Gastrointestinal involvement in Behcet's syndrome: a controlled study. Ann Rheum Dis 1996; 55:208-210

[27] Ehrlich GE. Vasculitis in Behcet's disease. Int Rev Immunol 1997; 14:81-88

[28] Ehrlich GE. Behcet's disease and emergence of thalidomide. Ann Intern Med 1998; 128:494-495

[29] Heymann RE, Ferraz MB, Quaresma MR, et al. The role of ambiental agents in Behcet's disease. Rev Rhum Engl Ed 1995; 62:343-348

[30] Yazici H. The place of Behcet's syndrome among the autoimmune diseases. Int Rev Immunol 1997; 14:1-10

[31] Yazici H, Tuzun Y, Pazarli H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behcet's syndrome. Ann Rheum Dis 1984; 43:783-789

[32] Lehner T. Behcet's syndrome and autoimmunity. BMJ 1967; 1:465-467

[33] Oshima Y, Shimizu T, Yokohari R, et al. Clinical studies on Behcet's syndrome. Ann Rheum Dis 1963; 22:36-45

[34] Aydintug AO, Tokgoz G, D'Cruz DP, et al. Antibodies to endothelial cell in patients with Behcet's disease. Clin Immunol Immunopathol 1993; 67:157-162

[35] Yamashita N. Hyperreactivity of neutrophils and abnormal T cell homeostasis: a new insight for pathogenesis of Behcet's disease. Int Rev Immunol 1997; 14:11-19

[36] Ural AU, Yalcin A, Beyan C, et al. Plasma endothelin-1 concentrations in patients with Behcet's disease. Scand J Rheumatol 1994; 23:322-325

[37] Direskeneli H, Keser G, D'Cruz D, et al. Anti-endothelial cell antibodies, endothelial proliferation and yon Willebrand factor antigen in Behcet's disease. Clin Rheumatol 1995; 14: 55-61

[38] Stowers SA, Leiboff RH, Wasserman AG, et al. Right ventricular thrombus formation in association with acute myocardial infarction: diagnosis by 2-dimensional echocardiography. Am J Cardiol 1983; 52:912-913

[39] Massumi R. Bedside diagnosis of right heart myxomas through detection of palpable tumor shocks and audible plops. Am Heart J 1983; 105:303-310

(*) From the Department of Pulmonary Medicine (Dr. Mogulkoc), Ege University, Izmir, Turkey; and the Departments of Cardiology (Dr. Burgess) and Pathology (Dr. Bishop), Wythenshawe Hospital, Manchester, United Kingdom.

Manuscript received August 12, 1999; revision accepted November 29, 1999.

Correspondence to: Nesrin Mogulkoc, MD, North West Lung Research Center, Wythenshawe Hospital, Southmoor Rd, Wythenshawe, Manchester, M239LT, United Kingdom; e-mail: 100046.

COPYRIGHT 2000 American College of Chest Physicians
COPYRIGHT 2000 Gale Group

Return to Behcet syndrome
Home Contact Resources Exchange Links ebay